• 1. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552

Recent Advances in the Study of 6-Methyl-1H-pyrrolo[2,3-b]pyridine-2-carbonitrile (CAS: 1934502-28-9)

6-Methyl-1H-pyrrolo[2,3-b]pyridine-2-carbonitrile (CAS: 1934502-28-9) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential as a key intermediate in the synthesis of bioactive molecules. Recent studies have focused on its applications in drug discovery, particularly in the development of kinase inhibitors and other therapeutic agents targeting various diseases, including cancer and inflammatory disorders.

One of the most notable advancements in the research of this compound is its role in the synthesis of novel kinase inhibitors. Kinases are critical regulators of cellular signaling pathways, and their dysregulation is often implicated in diseases such as cancer. Researchers have successfully utilized 6-Methyl-1H-pyrrolo[2,3-b]pyridine-2-carbonitrile as a scaffold to develop potent and selective inhibitors targeting specific kinases, such as JAK2 and EGFR. These inhibitors have shown promising results in preclinical studies, demonstrating efficacy in reducing tumor growth and inflammation.

In addition to its applications in kinase inhibition, recent studies have explored the compound's potential in modulating other biological targets. For instance, it has been investigated as a building block for the development of small-molecule modulators of protein-protein interactions (PPIs), which are notoriously difficult to target with traditional drug design approaches. The unique structural features of 6-Methyl-1H-pyrrolo[2,3-b]pyridine-2-carbonitrile make it a versatile tool for probing these complex interactions.

The synthetic routes to 6-Methyl-1H-pyrrolo[2,3-b]pyridine-2-carbonitrile have also been optimized in recent years, enabling more efficient and scalable production. Advances in catalytic methods, such as transition metal-catalyzed cross-coupling reactions, have significantly improved the yield and purity of the compound, facilitating its broader use in research and drug development.

Furthermore, computational studies have provided valuable insights into the molecular interactions and binding modes of derivatives of 6-Methyl-1H-pyrrolo[2,3-b]pyridine-2-carbonitrile. Molecular docking and dynamics simulations have been employed to predict the binding affinities and selectivity profiles of these compounds, guiding the rational design of next-generation therapeutics.

In conclusion, 6-Methyl-1H-pyrrolo[2,3-b]pyridine-2-carbonitrile (CAS: 1934502-28-9) continues to be a compound of great interest in the field of chemical biology and medicinal chemistry. Its versatility as a scaffold for drug discovery, coupled with recent advancements in synthetic and computational methodologies, positions it as a valuable tool for the development of novel therapeutic agents. Ongoing research is expected to further elucidate its potential applications and expand its utility in addressing unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)